RAF expression in human astrocytic tumors

International Journal of Molecular Medicine

Volumn 23, Issue 1, 2009, Pages 17-31

  Hagemann, Carsten ^a   Gloger, Jens ^a   Anacker, Jelena ^a   Said, Harun M ^a   Gerngras, Stefanie ^a   Künhel, Siglinde ^a   Meyer, Christoph ^b   Rapp, Ulf Rüdiger ^c   Kämmerer, Ulrike ^a   Vordermark, Dirk ^a   Flentje, Michael ^a   Roosen, Klaus ^a   Vince, Giles Hamilton ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

A RAF; Astrocytoma; B RAF; C RAF; Expression analysis; Glioblastoma multiforme; Glioma; Sequencing

Indexed keywords

A RAF KINASE; B RAF KINASE; PHOSPHOTRANSFERASE; PROTEIN C RAF; RAF PROTEIN; UNCLASSIFIED DRUG; MESSENGER RNA; MUTANT PROTEIN;

ARTICLE; ASTROCYTOMA; CELL PROLIFERATION; CONTROLLED STUDY; DOT HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL MOTION; CHEMISTRY; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

ASTROCYTOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMANS; MUTANT PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS A-RAF; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA;

EID: 61749097614     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000097     Document Type: Article

References (79)

1. Reifenberger G and Collins VP: Pathology and molecular genetics of astrocytic gliomas. J Mol Med 82: 656-670, 2004.
2. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C and Karim AB: Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20: 2076-2084, 2002.
3. Shaw E, Arusell R, Scheithauer B, O'Fallon J, O'Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Nichols D, Ivnik R, Hellman R, Curran W and Abrams R: Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/ Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20: 2267-2276, 2002.
4. Cavenee WK, Furnari FB, Nagane M, Huang H-JS, Newcomb EW, Bigner DD, Weller M, Berens ME, Plate KH, Israel MA, Noble MD and Kleihues P: Diffusely infiltrating astrocytomas. In: Pathology and Genetics of Tumors of the Nervous System. WHO Classification of Tumors. Kleihues P and Cavenee WK (eds.). IARC, Lyon, pp10-21, 2000.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
6. Reardon DA and Wen PY: Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11: 152-164, 2006.
7. Schrock E, Blume C, Meffert MC, du Manoir S, Bersch W, Kiessling M, Lozanowa T, Thiel G, Witkowski R, Ried T and Cremer T: Recurrent gain of chromosome arm 7q in low-grade astrocytic tumors studied by comparative genomic hybridization. Genes Chromosomes Cancer 15: 199-205, 1996.
8. Wessels PH, Twijnstra A, Kessels AG, Krijne-Kubat B, Theunissen PH, Ummelen MI, Ramaekers FC and Hopman AH: Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2. Genes Chromosomes Cancer 33: 279-284, 2002.
9. Kleihues P, Davis RL, Ohgaki H, Burger PC, Westphal M and Cavenee WK: Diffuse astrocytoma. In: Pathology and Genetics of Tumors of the Nervous System. World Health Organization Classification of Tumors. Kleihues P and Cavenee WK (eds.). IARC, Lyon, pp22-26, 2000.
10. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A and Collins VP: Deregulation of the p14ARF/Mdm2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60: 417-424, 2000.
11. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B and Nister M: Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52: 3213-3219, 1992.
12. Guha A, Dashner K, Black PM, Wagner JA and Stiles CD: Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 60: 168-173, 1995.
13. Guha A, Feldkamp MM, Lau N, Boss G and Pawson A: Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15: 2755-2765, 1997.
14. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE and Fuller GN: Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25: 55-57, 2000.
15. Ding H, Roncari L, Shannon P, Wu X, Lau N, Karaskova J, Gutmann DH, Squire JA, Nagy A and Guha A: Astrocyte specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 61: 3826-3836, 2001.
16. Hagemann C and Rapp UR: Isotype-specific functions of Raf kinases. Exp Cell Res 253: 34-46, 1999.
17. Peyssonnaux C and Eychene A: The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93: 53-62, 2001.
18. Beeram M, Patnaik A and Rowinsky EK: Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 23: 6771-6790, 2005.
19. Emuss V, Garnett M, Mason C and Marais R: Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity with B-RAF. Cancer Res 65: 9719-9726, 2005.
20. Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Min WS, Kim SH, Lee JY, Yoo NJ and Lee SH: Mutational analysis of the ARAF gene in human cancers. APMIS 113: 54-57, 2005.
21. Dhomen N and Marais R: New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17: 31-39, 2007.
22. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhönen S and Hemminki K: BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9: 3362-3368, 2003.
23. Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
24. Mercer KE and Pritchard CA: Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653: 25-40, 2003.
25. Storm SM and Rapp UR: Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 67: 201-210, 1993.
26. Rapp UR, Fensterle J, Albert S and Götz R: Raf kinases in lung tumor development. Adv Enzyme Regul 43: 183-195, 2003.
27. Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JHF, Dedhar S and Bally MB: Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther 5: 645-654, 2006.
28. Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T, Yusuff N, Rasheed BKA, Kieran MW, Laforme A, Bigner DD, Friedman HS and Rich JN: AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res 66: 8722-8730, 2006.
29. Knobbe CB, Reifenberger J and Reifenberger G: Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 108: 467-470, 2004.
30. Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P and Reis RM: Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol 109: 207-210, 2005.
31. Culmsee C, Gasser E, Hansen S, Tonn J-C, Wagner E and Goldbrunner R: Effects of Raf-1 siRNA on human cerebral microvascular endothelial cells: a potential therapeutic strategy for inhibition of tumor angiogenesis. Brain Res 1125: 147-154, 2006.
32. Jeuken J, van den Broecke C, Gijsen S, Boots-Sprenger S and Wesseling P: RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 114: 121-133, 2007.
33. Stojic J, Hagemann C, Haas S, Herbold C, Kühnel S, Gerngras S, Roggendorf W, Roosen K and Vince GH: Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci Res 60: 40-49, 2008.
34. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC and Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225, 2002.
35. Akslen LA, Andersen KJ and Bjerkvig R: Characteristics of human and rat glioma cells grown in a defined medium. Anticancer Res 8: 797-803, 1988.
36. Hagemann C, Meyer C, Stojic J, Eicker S, Gerngras S, Kühnel S, Roosen K and Vince GH: High efficiency transfection of glioma cell lines and primary cells for overexpression and RNAi experiments. J Neurosci Methods 156: 194-202, 2006.
37. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ and Marais R: B-Raf is a therapeutic target in melanoma. Oncogene 23: 6292-6298, 2004.
38. MAFFT Version 6. Multiple alignment program for amino acid or nucleotide sequences [http://align.bmr.kyushu-u.ac.jp/mafft/online/server/]
39. Boxshade 3.21. Pretty printing and shading of multiple alignment files [http://www.ch.embnet.org/software/BOX_form.html]
40. Hagemann C, Stojic J, Gerngras S, Kühnel S, Said HM, Patel R, Kämmerer U, Vordermark D, Roosen K and Vince GH: Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (Microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas. Oncol Rep 20: 301-308, 2008.
41. Primer 3 (v. 0.4.0) Pick primers from a DNA sequence [http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi]
42. Goldbrunner RH, Bouterfa H, Vince GH, Bernstein JJ, Roosen K and Tonn J-C: Transfection and dye premarking of human and rat glioma cell lines affects adhesion, migration and proliferation. Anticancer Res 17: 4467-4471, 1997.
43. Fransén K, Klintenäs M, Österström A, Dimberg J, Monstein H-J and Söderkvist P: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25: 527-533, 2004.
44. Eychène A, Barnier JV, Dezélée P, Marx M, Laugier D, Calogeraki I and Clothy G: Quail neuroretina c-Rmil (B-raf) proto-oncogene cDNAs encode two proteins of 93.5 and 95 kDa resulting from alternative splicing. Oncogene 7: 1315-1323, 1992.
45. Barnier JV, Papin C, Eychène A, Lecoq O and Calothy G: The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J Biol Chem 270: 23381-23389, 1995.
46. Eychène A, Dusanter-Fourt I, Barnier JV, Papin C, Charon M, Gisselbrecht S and Calothy G: Expression and activation of B-Raf kinase isoforms in human and murine leukemia cell lines. Oncogene 10: 1159-1165, 1995.
47. Ekstrand AJ, Sugawa N, James CD and Collins VP: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 89: 4309-4313, 1992.
48. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP and James CD: Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9: 2313-2320, 1994.
49. Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H and Troppmair J: Signaling through Ras-Raf-MEK-ERK: from basics to bedside. Curr Med Chem 14: 601-623, 2007.
50. Kiaris H and Spandidos DA: Mutations of ras gene in human tumours (review). Int J Oncol 7: 413-421, 1995.
51. Gömöri E, Dóczi T, Pajor L and Matolcsy A: Sporadic p53 mutations and absence of Ras mutations in glioblastomas. Acta Neurochir (Wien) 141: 593-599, 1999.
52. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R and Cancer Genome Project: Mechanism of activation of the Raf-ERK signaling pathway by oncogenic mutations of B-Raf. Cell 116: 855-867, 2004.
53. Garnett MJ, Rana S, Paterson H, Barford D and Marais R: Wild-type and mutant B-Raf activate c-Raf through distinct machanisms involving heterodimerization. Mol Cell 20: 963-969, 2005.
54. Rapp UR, Götz R and Albert S: BuCy RAFs drive cells into MEK addiction. Cancer Cell 9: 9-12, 2006.
55. Cianculli AM, Morace E, Coletta AM, Occhipinti E, Gandolfo GM, Leorardo G and Carapella CM: Investigation of genetic alterations associated with development and adverse outcome in patients with astrocytic tumor. J Neurooncol 48: 95-101, 2000.
56. Loeper S, Romeike BFM, Heckmann N, Jung V, Henn W, Feiden W, Zhang KD and Urbschat S: Frequent mitotic errors in tumor cells of genetically micro-heterogeneous glioblastomas. Cytogenet Cell Genet 94: 1-8, 2001.
57. Shapiro JR: Genetic alterations associated with adult diffuse astrocytic tumors. Am J Med Genet 115: 194-201, 2002.
58. Von Deimling A, Louis DN and Wiestler OD: Molecular pathways in the formation of gliomas. Glia 15: 328-338, 1995.
59. Duesberg P, Li R, Fabarius A and Hehlmann R: The chromosomal basis of cancer. Cell Oncol 27: 293-318, 2005.
60. Ciampi R, Knauf JA, Rabes HM, Fagin JA and Nikiforov YE: BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer. Cell Cycle 4: 547-548, 2005.
61. Rapp UR, Cleveland JL, Storm SM, Beck TW and Huleihel M: Transformation by Raf and myc oncogenes. In: Oncogenes and Cancer. Aaronson SA, et al (eds.) Japan Scl Soc Press, Tokyo/VNU Sci Press, Utrecht, pp53-74, 1987.
62. Said HM, Hagemann C, Staab A, Stojic J, Kühnel S, Vince GH, Flentje M, Roosen K and Vordermark D: Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1 (in human glioma in vitro and in vivo. Radiother Oncol 83: 398-405, 2007.
63. LaRocca RV, Rosenblum M, Westermark B and Israel MA: Patterns of proto-oncogene expression in human glioma cell lines. J Neurosci Res 24: 97-106, 1989.
64. Yokoyama T, Takano K, Yoshida A, Katada F, Sun P, Takenawa T, Andoh T and Endo T: DA-Raf1, a competent intrinsic dominant-negative antagonist of the Ras-ERK pathway, is required for myogenic differentiation. J Cell Biol 177: 781-793, 2007.
65. Yureyev A, Ono M, Goff SA, Macaluso F and Wennogle LP: Isoform-specific localization of A-Raf in mitochondria. Mol Cell Biol 20: 4870-4878, 2000.
66. Yuen ST, Davies H, Chan TL, Ho, JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R and Leung SY: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62: 6451-6455, 2002.
67. Houben R, Becker JC, Kappel A, Terheyden P, Bröcker E-B, Goetz R and Rapp UR: Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3: 6, 2004.
68. Hüser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, Sun X-M, Brown J, Marais R and Pritchard C: MEK kinase activity is not necessary for Raf-1 function. EMBO J 20: 1940-1951, 2001.
69. Woods D, Parry D, Cherwinski H, Bosch E, Lees E and McMahon M: Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17: 5598-5611, 1997.
70. Kerkhoff E and Rapp UR: High-intensity Raf signals convert mitotic cell cycling into cellular growth. Cancer Res 58: 1636-1640, 1998.
71. Garnett MJ and Marais R: Guilty as charged: B-Raf is a human oncogene. Cancer Cell 6: 313-319, 2004.
72. Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, van der Horst CMAM, Majoor DM, Shay JW, Mooi WJ and Peeper DS: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720-724, 2005.
73. Wajapeyee N, Serra RW, Zhu X, Mahalingam M and Green MR: Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132: 363-374, 2008.
74. Cornwell MM and Smith DE: A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem 268: 15347-15350, 1993.
75. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007.
76. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
77. Le Mellay V, Houben R, Troppmair J, Hagemann C, Mazurek S, Frey U, Beigel J, Weber C, Benz R, Eigenbrodt E and Rapp UR: Regulation of glycolysis by Raf protein serine/threonine kinases. Adv Enzyme Regul 42: 317-332, 2002.
78. Mazurek S, Drexler HC, Troppmair J, Eigenbrodt E and Rapp UR: Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism. Anticancer Res 27: 3963-3971, 2007.
79. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and Cantley LC: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233, 2008.